Swiss National Bank Sage Therapeutics, Inc. Transaction History

Swiss National Bank

$140 Billion
Q1 2024

A detailed history of Swiss National Bank transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Swiss National Bank holds 106,200 shares of SAGE stock, worth $1.13 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

106,200

Previous 106,200 -0.0%

Holding current value

$1.13 Million

Previous $2.3 Million 13.52%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 06, 2024	SELL	$17.1 - $22.26 $205,200 - $267,120	-12,000 Reduced 10.15%	106,200 $2.3 Million
Q3 2023 Nov 08, 2023	BUY	$16.75 - $48.98 $20,100 - $58,775	1,200 Added 1.03%	118,200 $2.43 Million
Q2 2023 Aug 09, 2023	BUY	$40.65 - $59.54 $60,975 - $89,310	1,500 Added 1.3%	117,000 $5.5 Million
Q1 2023 May 10, 2023	SELL	$37.27 - $46.57 $510,599 - $638,009	-13,700 Reduced 10.6%	115,500 $4.85 Million
Q4 2022 Feb 08, 2023	BUY	$32.2 - $43.61 $99,820 - $135,191	3,100 Added 2.46%	129,200 $4.93 Million

Q3 2022 Nov 09, 2022	BUY	$32.28 - $43.27 $25,824 - $34,616	800 Added 0.64%	126,100 $4.94 Million
Q1 2022 May 09, 2022	BUY	$30.71 - $45.71 $276,390 - $411,390	9,000 Added 7.74%	125,300 $4.15 Million
Q3 2021 Nov 08, 2021	BUY	$40.26 - $57.37 $20,130 - $28,685	500 Added 0.43%	116,300 $5.15 Million
Q2 2021 Aug 06, 2021	SELL	$54.88 - $79.29 $175,616 - $253,728	-3,200 Reduced 2.69%	115,800 $6.58 Million
Q1 2021 May 07, 2021	BUY	$70.65 - $96.76 $105,975 - $145,140	1,500 Added 1.28%	119,000 $8.91 Million
Q4 2020 Feb 05, 2021	SELL	$58.41 - $89.06 $11,682 - $17,812	-200 Reduced 0.17%	117,500 $10.2 Million
Q3 2020 Nov 09, 2020	BUY	$41.13 - $62.45 $78,147 - $118,655	1,900 Added 1.64%	117,700 $7.19 Million
Q2 2020 Aug 05, 2020	BUY	$25.95 - $43.15 $397,035 - $660,195	15,300 Added 15.22%	115,800 $4.82 Million
Q1 2020 May 08, 2020	BUY	$26.15 - $77.24 $44,455 - $131,308	1,700 Added 1.72%	100,500 $2.89 Million
Q4 2019 Feb 06, 2020	BUY	$60.18 - $154.77 $150,450 - $386,925	2,500 Added 2.6%	98,800 $7.13 Million
Q3 2019 Nov 12, 2019	BUY	$140.29 - $189.96 $210,435 - $284,940	1,500 Added 1.58%	96,300 $13.5 Million
Q2 2019 Aug 02, 2019	BUY	$157.85 - $183.09 $1.48 Million - $1.72 Million	9,400 Added 11.01%	94,800 $17.4 Million
Q1 2019 May 10, 2019	BUY	$89.33 - $163.65 $259,057 - $474,585	2,900 Added 3.52%	85,400 $13.6 Million
Q4 2018 Feb 13, 2019	BUY	$81.94 - $139.71 $114,716 - $195,594	1,400 Added 1.73%	82,500 $7.9 Million
Q3 2018 Nov 08, 2018	BUY	$138.11 - $169.04 $138,110 - $169,040	1,000 Added 1.25%	81,100 $11.5 Million
Q2 2018 Aug 09, 2018	BUY	$140.36 - $175.76 $98,252 - $123,032	700 Added 0.88%	80,100 $12.5 Million
Q1 2018 May 04, 2018	BUY	$152.15 - $192.33 $1.99 Million - $2.52 Million	13,100 Added 19.76%	79,400 $12.8 Million
Q4 2017 Feb 07, 2018	BUY	$60.72 - $167.34 $789,360 - $2.18 Million	13,000 Added 24.39%	66,300 $10.9 Million
Q3 2017 Nov 03, 2017	BUY	$61.4 - $88.52 $3.27 Million - $4.72 Million	53,300	53,300 $3.32 Million

Others Institutions Holding SAGE

# of Institutions

222

Shares Held

52.7M

Call Options Held

207K

Put Options Held

191K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $631M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Account

Swiss National Bank Sage Therapeutics, Inc. Transaction History